The histone acetyltransferase PCAF regulates p21 transcription through stress-induced acetylation of histone H3

Cell Cycle

Volumn 11, Issue 13, 2012, Pages 2458-2466

  Love, Ian M ^a,b   Sekaric, Pedja ^a   Shi, Dingding ^a   Grossman, Steven R ^a,b   Androphy, Elliot J ^a,c  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ARF; DNA damage; Histone acetylation; p21; p53; PCAF

Indexed keywords

HISTONE ACETYLTRANSFERASE; HISTONE ACETYLTRANSFERASE PCAF; HISTONE H3; LYSINE; NUTLIN 3; PROTEIN P14; PROTEIN P21; PROTEIN P300; PROTEIN P53;

ARTICLE; CELL CYCLE ARREST; CELL FUNCTION; CHROMATIN; DNA DAMAGE; GENE SILENCING; HISTONE ACETYLATION; HUMAN; NULL CELL; PROTEIN EXPRESSION; STRESS;

EID: 84863794131     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.20864     Document Type: Article

References (63)

1. Junttila MR, Evan GI. p53 - a Jack of all trades but master of none. Nat Rev Cancer 2009; 9:821-9; PMID:19776747; http://dx.doi.org/10.1038/nrc2728.
2. Banito A, Rashid ST, Acosta JC, Li S, Pereira CF, Geti I, et al. Senescence impairs successful reprogramming to pluripotent stem cells. Genes Dev 2009; 23:2134-9; PMID:19696146; http://dx.doi.org/10.1101/gad.1811609.
3. Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, Nakagawa M, et al. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 2009; 460:1132-5; PMID:19668191; http://dx.doi.org/10.1038/nature08235.
4. Li H, Collado M, Villasante A, Strati K, Ortega S, Cañamero M, et al. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 2009; 460:1136-9; PMID:19668188; http://dx.doi.org/10.1038/nature08290.
5. Bedelbaeva K, Snyder A, Gourevitch D, Clark L, Zhang XM, Leferovich J, et al. Lack of p21 expression links cell cycle control and appendage regeneration in mice. Proc Natl Acad Sci USA 2010; 107:5845-50; PMID:20231440; http://dx.doi.org/10.1073/pnas.1000830107.
6. Pang LY, Scott M, Hayward RL, Mohammed H, Whitelaw CB, Smith GC, et al. p21(WAF1) is component of a positive feedback loop that maintains the p53 transcriptional program. Cell Cycle 2011; 10:932-50; PMID:21368573; http://dx.doi.org/10.4161/cc.10.6.15012.
7. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009; 9:400-14; PMID:19440234; http://dx.doi.org/10. 1038/nrc2657.
8. Schiltz RL, Nakatani Y. The PCAF acetylase complex as a potential tumor suppressor. Biochim Biophys Acta 2000; 1470:37-53; PMID:10722926.
9. Grossman SR. p300/CBP/p53 interaction and regulation of the p53 response. Eur J Biochem 2001;268:2773-8; PMID:11358491; http://dx.doi.org/10.1046/j.1432- 327.2001.02226.x.
10. Gamper AM, Roeder RG. Multivalent binding of p53 to the STAGA complex mediates coactivator recruitment after UV damage. Mol Cell Biol 2008; 28:2517-27; PMID:18250150; http://dx.doi.org/10.1128/MCB.01461-07.
11. Barlev NA, Liu L, Chehab NH, Mansfield K, Harris KG, Halazonetis TD, et al. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol Cell 2001; 8:1243-54; PMID:11779500; http://dx.doi.org/10.1016/S1097-2765(01)00414-2.
12. Liu L, Scolnick DM, Trievel RC, Zhang HB, Marmorstein R, Halazonetis TD, et al. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol Cell Biol 1999;19:1202-9; PMID:9891054.
13. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, et al. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 1998; 12:2831-41; PMID:9744860; http://dx.doi.org/10.1101/gad.12.18.2831.
14. Lill NL, Grossman SR, Ginsberg D, DeCaprio J, Livingston DM. Binding and modulation of p53 by p300/CBP coactivators. Nature 1997; 387:823-7; PMID:9194565; http://dx.doi.org/10.1038/42981.
15. Scolnick DM, Chehab NH, Stavridi ES, Lien MC, Caruso L, Moran E, et al. CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein. Cancer Res 1997; 57:3693-6; PMID:9288775.
16. Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS, Kelly K. Recruitment of p300/CBP in p53-dependent signal pathways. Cell 1997; 89:1175-84; PMID:9215639; http://dx.doi.org/10.1016/S0092-8674(00)80304-9.
17. Gu W, Shi XL, Roeder RG. Synergistic activation of transcription by CBP and p53. Nature 1997;387:819-23; PMID:9194564; http://dx.doi.org/10.1038/42972.
18. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997; 90:595-606; PMID:9288740; http://dx.doi.org/10.1016/S0092-8674(00)80521-8.
19. Di Stefano V, Soddu S, Sacchi A, D'Orazi G. HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p21Waf1 after nonapoptotic DNA damage. Oncogene 2005; 24:5431-42; PMID:15897882; http://dx.doi.org/10.1038/sj.onc.1208717.
20. Yang XJ, Ogryzko VV, Nishikawa J, Howard BH, Nakatani Y. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 1996; 382:319-24; PMID:8684459; http://dx.doi.org/10.1038/382319a0.
21. Ogryzko VV, Kotani T, Zhang X, Schiltz RL, Howard T, Yang XJ, et al. Histone-like TAFs within the PCAF histone acetylase complex. Cell 1998; 94:35-44; PMID:9674425; http://dx.doi.org/10.1016/S0092-8674(00)81219-2.
22. Poux AN, Marmorstein R. Molecular basis for Gcn5/PCAF histone acetyltransferase selectivity for histone and nonhistone substrates. Biochemistry 2003;42:14366-74; PMID:14661947; http://dx.doi.org/10.1021/ bi035632n.
23. Schiltz RL, Mizzen CA, Vassilev A, Cook RG, Allis CD, Nakatani Y. Overlapping but distinct patterns of histone acetylation by the human coactivators p300 and PCAF within nucleosomal substrates. J Biol Chem 1999; 274:1189-92; PMID:9880483; http://dx.doi.org/10.1074/jbc.274.3.1189.
24. Le Cam L, Linares LK, Paul C, Julien E, Lacroix M, Hatchi E, et al. E4F1 is an atypical ubiquitin ligase that modulates p53 effector functions independently of degradation. Cell 2006; 127:775-88; PMID:17110336; http://dx.doi.org/10.1016/j.cell.2006.09.031.
25. Hoffmann A, Spengler D. A new coactivator function for Zac1's C2H2 zinc finger DNA-binding domain in selectively controlling PCAF activity. Mol Cell Biol 2008; 28:6078-93; PMID:18663001; http://dx.doi.org/10.1128/MCB.00842-08.
26. Grossman SR, Deato ME, Brignone C, Chan HM, Kung AL, Tagami H, et al. Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science 2003; 300:342-4; PMID:12690203; http://dx.doi.org/10.1126/science.1080386.
27. Shi D, Pop MS, Kulikov R, Love IM, Kung AL, Grossman SR. CBP and p300 are cytoplasmic E4 polyubiquitin ligases for p53. Proc Natl Acad Sci USA 2009; 106:16275-80; PMID:19805293; http://dx.doi.org/10.1073/pnas.0904305106.
28. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303:844-8; PMID:14704432; http://dx.doi.org/10.1126/science. 1092472.
29. Basile JR, Eichten A, Zacny V, Münger K. NFkappaB-mediated induction of p21(Cip1/Waf1) by tumor necrosis factoralpha induces growth arrest and cytoprotection in normal human keratinocytes. Mol Cancer Res 2003; 1:262-70; PMID:12612054.
30. Ma S, Tang J, Feng J, Xu Y, Yu X, Deng Q, et al. Induction of p21 by p65 in p53 null cells treated with Doxorubicin. Biochim Biophys Acta 2008; 1783:935-40; PMID:18269916; http://dx.doi.org/10.1016/j.bbamcr.2008.01.008.
31. Zhou Y, Li G, Ji Y, Liu C, Zhu J, Lu Y. Cytoplasmic p21 induced by p65 prevents doxorubicin-induced cell death in pancreatic carcinoma cell line. J Biomed Sci 2012; 19:15; PMID:22305266; http://dx.doi.org/10.1186/1423-0127-19-5.
32. Linares LK, Kiernan R, Triboulet R, Chable-Bessia C, Latreille D, Cuvier O, et al. Intrinsic ubiquitination activity of PCAF controls the stability of the oncoprotein Hdm2. Nat Cell Biol 2007; 9:331-8; PMID:17293853; http://dx.doi.org/10.1038/ncb1545.
33. Jiang H, Lu H, Schiltz RL, Pise-Masison CA, Ogryzko VV, Nakatani Y, et al. PCAF interacts with tax and stimulates tax transactivation in a histone acetyl-transferase-independent manner. Mol Cell Biol 1999;19:8136-45; PMID:10567539.
34. Marmorstein R. Structure of histone acetyltransferases. J Mol Biol 2001; 311:433-44; PMID:11492997; http://dx.doi.org/10.1006/jmbi.2001.4859.
35. Jin Q, Yu LR, Wang L, Zhang Z, Kasper LH, Lee JE, et al. Distinct roles of GCN5/PCAF-mediated H3K9ac and CBP/p300-mediated H3K18/27ac in nuclear receptor transactivation. EMBO J 2011; 30:249-62; PMID:21131905; http://dx.doi.org/10.1038/emboj.2010.318.
36. Kasper LH, Thomas MC, Zambetti GP, Brindle PK. Double null cells reveal that CBP and p300 are dispensable for p53 targets p21 and Mdm2 but variably required for target genes of other signaling pathways. Cell Cycle 2011; 10:212-21; PMID:21220944; http://dx.doi.org/10.4161/cc.10.2.14542.
37. Knights CD, Catania J, Di Giovanni S, Muratoglu S, Perez R, Swartzbeck A, et al. Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate. J Cell Biol 2006; 173:533-44; PMID:16717128; http://dx.doi.org/10.1083/jcb.200512059.
38. Chao C, Wu Z, Mazur SJ, Borges H, Rossi M, Lin T, et al. Acetylation of mouse p53 at lysine 317 negatively regulates p53 apoptotic activities after DNA damage. Mol Cell Biol 2006; 26:6859-69; PMID:16943427; http://dx.doi.org/10. 1128/MCB.00062-06.
39. Pickard A, Wong PP, McCance DJ. Acetylation of Rb by PCAF is required for nuclear localization and keratinocyte differentiation. J Cell Sci 2010; 123:3718-26; PMID:20940255; http://dx.doi.org/10.1242/jcs.068924.
40. Sankala HM, Hait NC, Paugh SW, Shida D, Lépine S, Elmore LW, et al. Involvement of sphingosine kinase 2 in p53-independent induction of p21 by the chemotherapeutic drug doxorubicin. Cancer Res 2007; 67:10466-74; PMID:17974990; http://dx.doi.org/10.1158/0008-5472.CAN-07-2090.
41. Martin BT, Kleiber K, Wixler V, Raab M, Zimmer B, Kaufmann M, et al. FHL2 regulates cell cycle-dependent and doxorubicin-induced p21Cip1/Waf1 expression in breast cancer cells. Cell Cycle 2007; 6:1779-88; PMID:17682292; http://dx.doi.org/10.4161/cc.6.14.4448.
42. Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev 1998; 12:599-606; PMID:9499396; http://dx.doi.org/10.1101/gad.12.5. 599.
43. Pogo BG, Allfrey VG, Mirsky AE. RNA synthesis and histone acetylation during the course of gene activation in lymphocytes. Proc Natl Acad Sci USA 1966; 55:805-12; PMID:5219687; http://dx.doi.org/10.1073/pnas.55.4.805.
44. Allfrey VG, Faulkner R, Mirsky AE. Acetylation and methylation of histones and their possible role in the regulation of rna synthesis. Proc Natl Acad Sci USA 1964; 51:786-94; PMID:14172992; http://dx.doi.org/10.1073/pnas.51. 5.786.
45. Rojas JR, Trievel RC, Zhou J, Mo Y, Li X, Berger SL, et al. Structure of Tetrahymena GCN5 bound to coenzyme A and a histone H3 peptide. Nature 1999; 401:93-8; PMID:10485713; http://dx.doi.org/10.1038/43487.
46. Clements A, Rojas JR, Trievel RC, Wang L, Berger SL, Marmorstein R. Crystal structure of the histone acetyltransferase domain of the human PCAF transcriptional regulator bound to coenzyme A. EMBO J 1999; 18:3521-32; PMID:10393169; http://dx.doi.org/10.1093/emboj/18.13.3521.
47. Kuo MH, Brownell JE, Sobel RE, Ranalli TA, Cook RG, Edmondson DG, et al. Transcription-linked acetylation by Gcn5p of histones H3 and H4 at specific lysines. Nature 1996; 383:269-72; PMID:8805705; http://dx.doi.org/10.1038/ 383269a0.
48. Grant PA, Eberharter A, John S, Cook RG, Turner BM, Workman JL. Expanded lysine acetylation specificity of Gcn5 in native complexes. J Biol Chem 1999; 274:5895-900; PMID:10026213; http://dx.doi.org/10.1074/jbc.274.9.5895.
49. Donner AJ, Szostek S, Hoover JM, Espinosa JM. CDK8 is a stimulus-specific positive coregulator of p53 target genes. Mol Cell 2007; 27:121-33; PMID:17612495; http://dx.doi.org/10.1016/j.molcel.2007.05.026.
50. Espinosa JM, Verdun RE, Emerson BM. p53 functions through stress- and promoter-specific recruitment of transcription initiation components before and after DNA damage. Mol Cell 2003; 12:1015-27; PMID:14580351; http://dx.doi.org/ 10.1016/S1097-2765(03)00359-9.
51. Gomes NP, Espinosa JM. Gene-specific repression of the p53 target gene PUMA via intragenic CTCF-Cohesin binding. Genes Dev 2010; 24:1022-34; PMID:20478995; http://dx.doi.org/10.1101/gad.1881010.
52. Cheung P, Tanner KG, Cheung WL, Sassone-Corsi P, Denu JM, Allis CD. Synergistic coupling of histone H3 phosphorylation and acetylation in response to epidermal growth factor stimulation. Mol Cell 2000; 5:905-15; PMID:10911985; http://dx.doi.org/10.1016/S1097-2765(00)80256-7.
53. Lo WS, Trievel RC, Rojas JR, Duggan L, Hsu JY, Allis CD, et al. Phosphorylation of serine 10 in histone H3 is functionally linked in vitro and in vivo to Gcn5-mediated acetylation at lysine 14. Mol Cell 2000; 5:917-26; PMID:10911986; http://dx.doi.org/10.1016/S1097-2765(00)80257-9.
54. Meyer KD, Donner AJ, Knuesel MT, York AG, Espinosa JM, Taatjes DJ. Cooperative activity of cdk8 and GCN5L within Mediator directs tandem phosphoacetylation of histone H3. EMBO J 2008; 27:1447-57; PMID:18418385.
55. Yamauchi T, Yamauchi J, Kuwata T, Tamura T, Yamashita T, Bae N, et al. Distinct but overlapping roles of histone acetylase PCAF and of the closely related PCAF-B/GCN5 in mouse embryogenesis. Proc Natl Acad Sci USA 2000; 97:11303-6; PMID:11027331; http://dx.doi.org/10.1073/pnas.97.21.11303.
56. Perez RE, Knights CD, Sahu G, Catania J, Kolukula VK, Stoler D, et al. Restoration of DNA-binding and growth-suppressive activity of mutant forms of p53 via a PCAF-mediated acetylation pathway. J Cell Physiol 2010; 225:394-405; PMID:20589832; http://dx.doi.org/10.1002/jcp.22285.
57. Zhu C, Qin YR, Xie D, Chua DT, Fung JM, Chen L, et al. Characterization of tumor suppressive function of P300/CBP-associated factor at frequently deleted region 3p24 in esophageal squamous cell carcinoma. Oncogene 2009; 28:2821-8; PMID:19525977; http://dx.doi.org/10.1038/onc.2009.137.
58. Beckerman R, Donner AJ, Mattia M, Peart MJ, Manley JL, Espinosa JM, et al. A role for Chk1 in blocking transcriptional elongation of p21 RNA during the S-phase checkpoint. Genes Dev 2009; 23:1364-77; PMID:19487575; http://dx.doi.org/10.1101/gad.1795709.
59. Morachis JM, Murawsky CM, Emerson BM. Regulation of the p53 transcriptional response by structurally diverse core promoters. Genes Dev 2010; 24:135-47; PMID:20040571; http://dx.doi.org/10.1101/gad.1856710.
60. Gomes NP, Espinosa JM. Disparate chromatin landscapes and kinetics of inactivation impact differential regulation of p53 target genes. Cell Cycle 2010; 9:3428-37; PMID:20818159; http://dx.doi.org/10.4161/cc.9.17.12998.
61. Hill R, Madureira PA, Waisman DM, Lee PW. DNAPKCS binding to p53 on the p21WAF1/CIP1 promoter blocks transcription resulting in cell death. Oncotarget 2011; 2:1094-108; PMID:22190353.
62. Zeng PY, Vakoc CR, Chen ZC, Blobel GA, Berger SL. In vivo dual cross-linking for identification of indirect DNA-associated proteins by chromatin immuno-precipitation. Biotechniques 2006; 41:694; PMID:17191611; http://dx.doi.org/10.2144/000112297.
63. Carey MF, Peterson CL, Smale ST. Chromatin immuno-precipitation (ChIP). Cold Spring Harb Protoc 2009; 2009:5279; PMID:20147264; http://dx.doi.org/10. 1101/pdb.prot5279.